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Abstract
Purpose—There is debate within the genetics community about the optimal term to describe 
genetic variants unrelated to the test indication, but potentially important for health. Given the lack 
of consensus and the importance of adopting terminology that promotes effective clinical 
communication, we sought the opinion of clinical genetics patients.
Methods—Surveys and focus groups with two patient populations were conducted. Eighty-eight 
survey participants were asked to rank four terms according to how well each describes results 
unrelated to the test indication: incidental findings, secondary findings, additional findings, and 
ancillary findings. Participants in six focus groups were guided through a free-thought exercise to 
describe desired attributes of such a term, and then asked to formulate a best term to represent this 
concept.
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Results—The term additional findings had the most first choice rankings by survey participants, 
followed by secondary findings, incidental findings, and ancillary findings. Most focus group 
participants preferred the term additional findings; they also described reasons why other terms 
were not optimal.
Conclusion—Additional findings was preferred as both more neutral and accessible than other 
terms currently in use. Patient perceptions and comprehension will be framed by the terminology. 
Thus, patient opinions should be considered by medical genetics professionals.
Keywords
incidental findings; secondary findings; additional findings; ancillary findings; genome 
sequencing; clinical genomics
INTRODUCTION
As technology advances, genomic sequencing is becoming a more accessible and reliable 
tool for characterizing the molecular nature of disease, leading to the increasing use of large 
scale sequencing tests such as multi-gene panels, exome sequencing, and genome 
sequencing. Large scale sequencing may uncover variants of potential clinical significance 
unrelated to the disease that prompted the evaluation. In other words, these variants may be 
related to risks of developing a different disease(s) or they may identify carrier status for 
recessive diseases. For example, an exome sequencing test performed for a neurological 
disorder with unknown etiology may identify a pathogenic variant in MYBPC3 associated 
with increased risk of hypertrophic cardiomyopathy. Individuals in the clinical genetics 
community commonly refer to these types of results as incidental findings. This terminology 
arose because of similarities to other medical contexts, such as radiologists identifying 
atypical or abnormal imaging findings unrelated to a presenting condition (e.g., a thyroid 
mass on a chest radiograph performed for shortness of breath1). However, the American 
College of Medical Genetics (ACMG) recommendations for reporting incidental findings in 
clinical exome and genome sequencing defines incidental findings as, “the results of a 
deliberate search for pathogenic or likely pathogenic alterations in genes that are not 
apparently relevant to a diagnostic indication for which the sequencing test was ordered.”2 
Thus, in the context of genomics, informatics may be used to include (or exclude) specific 
variants unrelated to the indication for testing, making identification of these findings quite 
different from identification of incidental findings in other medical specialties.
For this and other reasons, terms other than incidental findings have made their way into the 
lexicon: secondary variants, unexpected results, unsolicited findings, unrelated findings, and 
non-pertinent findings have all been proposed.3-9 While the relative merits and potential 
controversy regarding some of these terms has been reviewed, 10,11 we are not aware of a 
study that has sought data on patient preferences in this regard. It is essential to identify 
patient preferences because the language clinicians use to explain these types of results has 
the potential either to promote effective patient decision making or to cause confusion or 
misperceptions about the nature of the findings, undermining effective patient decision 
making. Here we present the results of two studies of two patient populations as part of the 
Clinical Sequencing Exploratory Research (CSER) consortium: (1) a survey of University of 
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Washington (UW) Division of Medical Genetics patients’ perspectives and preferences 
regarding terminology used to describe genetic findings unrelated to the test indication and 
(2) data from focus groups conducted by investigators at the University of North Carolina 
(UNC) at Chapel Hill regarding patient reactions to the term incidental findings.
METHODS
The terminology question was raised in the context of the National Human Genome 
Research Institute (NHGRI)/National Cancer Institute (NCI)-funded CSER consortium 
which is exploring the integration of genomic sequencing technology into clinical care.12 
Two CSER consortium projects independently explored this issue in the context of their 
studies.
The CSER UW New Exome Technology in (NEXT) Medicine study is a randomized control 
trial targeting individuals who presented to medical genetics for testing related to colorectal 
cancer. The study is comparing two arms: (1) usual clinical care genetic testing for 
hereditary colorectal cancer/polyps (CRCP) (usual care group) and (2) usual clinical care 
genetic testing for CRCP plus exome sequencing (exome sequencing group).13 Participants 
receive diagnostic as well as other types of genomic findings. The CSER UNC North 
Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing (NCGENES) study, 
is investigating best practices for using whole exome sequencing for clinical diagnosis in 
adult and pediatric patients who have symptoms or a condition with a suspected genetic 
etiology that has not yet been identified. NCGENES participants also receive additional 
genomic findings.
Development of survey and focus group materials
A survey to explore terminology preferences in the UW adult genetics population was 
developed by UW medical genetics faculty, a genetic counselor, a medical student, and a 
research coordinator. The concept of incidental findings was defined in the survey as “gene 
changes that are not related to the initial reason the clinic ordered the genetic test, but may 
be important for the patient’s health care.” Four terms were selected from the literature by 
the interdisciplinary UW team and participants were asked to rank them: incidental findings, 
secondary findings, additional findings, and ancillary findings. Participants were also asked, 
“How strongly do you feel there are better and worse choices?” on a scale of 1 (it does not 
matter) to 5 (some are better), and they had the option to suggest a different term. Basic 
demographic information was also collected including: sex, age group, and race and 
ethnicity. Both a paper and an electronic survey were developed. Terms were presented in a 
randomized order in the electronic survey to evaluate if the order in which the terms were 
presented affected rankings. The survey is available as Supplemental Figure S1. The UW 
Institutional Review Board approved the study (UW IRB Biomedical Committee B, 
#41829).
UNC researchers with experience in social science and ethnographic research and clinical 
genetic counseling developed all UNC focus group materials. The final materials consisted 
of: 1) a moderator guide, 2) a 13-item questionnaire (8 demographic items and 5 genetic 
testing experience items), 3) a 1-page handout providing an overview of whole exome 
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sequencing and diagnostic versus incidental information, and 4) a 1-page handout with a 
vignette describing the exome diagnostic testing experience of a hypothetical patient with a 
neuromuscular condition. The format for the moderator guide was based on a traditional 
funneling approach which guides discussion from broad to more specific questions.14,15 
This format was used to enable incorporation of new knowledge and allow opinion 
formation about exome sequencing and the possibility of findings not related to the 
diagnostic indication. The informational handout was developed based on NCGENES 
education materials. It described incidental information as genetic results “completely 
unrelated to the person’s symptoms”. The moderator guide further clarified these results as 
“any findings that are not related to the reason for ordering the test.”This language is similar 
to the description of incidental information provided in the UW surveys though it should be 
noted that the concept was not described identically to both participant groups. Possible 
categories of these findings were described to participants to potentially include diagnostic 
results for a different medical condition (with subcategories of varying severity and ability to 
treat or prevent), carrier status and statistical associations for pharmacogenetics interactions 
and risks for common diseases. The study was approved by the UNC IRB (UNC protocol 
#13-3466). The development of focus group materials was not informed by the contents or 
results of the UW survey and vice versa.
Population
Adults who presented for medical genetics evaluation at UW were recruited to the survey 
study in one of two ways: they were already enrolled in the UW NEXT Medicine study, or 
they were registered patients being seen at the UW Genetic Medicine clinic. All NEXT 
Medicine participants had consented to be contacted regarding additional study related 
activities and were emailed a link to the electronic survey. The concept of incidental findings 
had been introduced by study personnel and in materials during informed consent as ‘genetic 
information (results) that may include risks for “extra” diseases other than CRCP’. Those 
randomized to the exome sequencing arm were also asked to complete a document eliciting 
preferences for types of incidental findings, and subsequently those findings were returned. 
The UW Genetic Medicine clinic patients not in the NEXT Medicine study, being seen for a 
variety of indications, could leave their completed paper survey in a collection box at the end 
of their clinic visit, or use a prepaid return envelope to mail it. Surveys were not given to 
patients being evaluated for neurocognitive decline or neurodevelopment disorders such as 
autism.
UNC Focus Group participants were recruited from adult patients or the parents of pediatric 
patients or intellectually disabled adult patients who had been evaluated through a UNC 
Genetics Clinic appointment (pediatric, adult or cancer) within the previous two years. To be 
eligible, genetic testing had to have been conducted as part of their (or their child’s) 
evaluation, they had to be comfortable participating in the Focus Group discussion in 
English, and they had to live within approximately 30-40 minute driving time of the Focus 
Group location near UNC Hospitals. An introduction letter was mailed to eligible 
individuals and follow-up phone calls recruited potential participants who had not opted out.
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Implementation
Electronic surveys were emailed to 75 UW NEXT Medicine study participants in July 2015 
(37 in the usual care group and 38 in the exome sequencing group); they were given 2 weeks 
to respond. A reminder email was sent to those who had yet to respond with 1 week left in 
the survey time period. Paper surveys were distributed to UW Genetic Medicine clinic 
patients not already enrolled in the NEXT Medicine study during the check-in and intake 
process of their clinic visit. Responses were collected during 6 clinic days over a period of 5 
weeks between June 25, 2015 and July 30, 2015.
Six UNC focus groups were held in the fall of 2013. Each session lasted approximately 2 
hours, dinner was provided and participants received $40. Each focus group contained 3-12 
participants who were grouped according to whether they were an adult patient (4 groups: 2 
hereditary cancer, 1 general genetics and 1 mixed) or the parent/guardian of a patient (2 
groups). The first session served as a pilot and minor modifications were subsequently made 
to the Moderator Guide. An experienced focus group moderator (JO) led all sessions. At 
least one additional research team member was present at each session to take notes. 
Sessions were audio recorded and transcribed.
Analyses
Descriptive statistics were compiled for survey responses from UW NEXT Medicine 
participants and UW genetic medicine clinic patients. Fisher's exact tests were used to 
evaluate whether sex, age group, race or population (NEXT Medicine vs. clinic) affected 
respondents first choice term and how strongly they felt that there is a better or worse term. 
Tests were not corrected for multiple contrasts, given that they were descriptive.
Consistency across UNC focus groups was supported through use of the same researcher to 
conduct each session following an established moderator guide. Verbatim transcripts of 
focus groups were analyzed using an iterative process for content analysis.14,16 Each 
transcript was read independently for context and discussed as a group alongside the session 
notes. A procedure for analysis was developed with agreement from all members of the 
UNC research team. Transcripts were redistributed and read a second time grouping 
(unitizing), relevant themes based on specific moderator guide prompts. Themes were 
discussed and refined through group discussion. After consensus was reached on the 
definition of each theme, a third read of transcripts was conducted at which time themes 
were applied (coded) and exemplar quotes identified. Descriptive statistics were utilized for 
responses to the demographic and genetic experience survey.
RESULTS
Demographics and response rate
Of the 88 UW survey respondents (57 NEXT Medicine study participants and 31 Genetic 
Medicine clinic patients), complete data on terminology preferences were available for 73. 
One of the 31 UW clinic patients did not select any of the choices and 10 of the 31 only 
selected their 1st choice. Additionally, 7 of the 57 UW NEXT Medicine study respondents 
provided 2 rankings for the same term. For consistency, the lowest ranking for each 
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duplicated term was omitted. Thus, the total number of respondents with first choice 
rankings was 87. Seventy seven participants made second and third choice rankings and 73 
participants ranked all four terms. Among those 57 UW NEXT Medicine study respondents, 
significantly more responded from the exome sequencing group (87%) than the usual care 
group (65%) (chi-square 4.96; p = 0.026). Survey respondents’ demographic characteristics 
are listed in Table 1. There was a relatively equal representation of both sexes (47% males 
and 53% females). The majority of respondents (73/88) identified as White. Additionally, 
the majority (88%) of the respondents were between 30 and 70 years old.
A total of 40 individuals participated in one of the six UNC focus groups and 37 completed 
the questionnaire (Table 2). Participants were predominantly female (73%), white (73%), 
held a college degree (64.9%) and had health insurance (89.2%). Of the 9 parents of 
pediatric patients or intellectually disabled adult patients who participated, the mean age of 
their children was 18 years old (s.d. 9.86; range 6-35). Although all were known to have had 
at least one genetic test, 5 (13.5%) indicated they had never had genetic testing or were 
unsure. In addition, 32.4% percent did not indicate they understood the meaning of the 
genetic testing. Most (75.7%) had not heard about exome sequencing prior to the focus 
group.
Terminology preferences
The ranking of terms from the UW survey is presented in Figure 1. Among first choice 
rankings, nearly 2/3 chose additional findings (51/87) as the overall first choice ranking. 
One-fifth (17/87) chose secondary findings as their first choice; 13% percent chose 
incidental findings and 9% chose ancillary findings. There was no significant difference in 
first choice responses between participants in the UW NEXT Medicine study who responded 
to the electronic survey and UW Genetic Medicine clinic patients who used the paper survey 
(Fisher's exact p = 0.09). There was also no difference in survey responses based on race, 
sex or age group. Two participants provided comments explaining the reasoning behind their 
choices. One stated, “We did not like the “incidental” findings choice because it conveyed a 
sense of unimportance where it may, in fact, be very important to the patient.” The other 
respondent included a comment about each term: 1) Secondary Findings - "I like this one the 
best because I feel like it is very specific in describing the findings relative to the primary 
work,” 2) ancillary findings - "… this one draws a connection between the primary and 
"secondary" findings,” 3) additional findings - "… implies that there is some connection 
between the findings," 4) incidental findings – “…demotes the importance of the findings, 
whereas they might in fact be important.”
Survey respondents were also given the option to suggest a different term. The term 
“unrelated genetic findings” was listed twice - once by a NEXT Medicine study participant 
and once by a UW Genetic Medicine clinic patient. The term “supplemental findings” was 
listed 3 times by UW NEXT Medicine study participants. Other terms suggested only once 
include “secondary/tertiary,” “subsidiary,” “unanticipated,” “further,” and “collateral 
findings.” Some participants suggested modification of additional, such as “additional 
genetic” and “significant additional findings.”
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When UNC focus group participants were asked to reflect specifically on the term 
“incidental finding,” most participants preferred a more neutral term.
"The word ‘incidental’ sounds trivial when you’re talking about ALS or, you know, 
Alzheimer’s or something… I think that incidental is ‘Am I going to pass on green 
eyes?’ Much more than ‘Am I going to pass on ALS?’”
"I would prefer a different category, one that implies something that may be 
meaningful or may need further follow-up or something…”
"If it’s incidental to you, it may not be to me."
Tasked with suggesting a better term, 5 of the 6 groups settled upon the term “additional”; 
the other group felt “incidental” was fine to use, as long as the clinician explained what was 
intended.
“’Additional’ - that way it doesn’t seem threatening”
"I like that, ‘additional findings’, cause that’s something I’m more familiar with 
that term. And so, and I would take that – doesn’t mean that’s negative or positive. 
It’s just this is what has shown up.”
"I find myself wishing I had a thesaurus for looking up other words.
Survey participant interest level
In the UW study, participants were asked to rate on a scale of 1 to 5 how strongly they felt 
that some terms were better than others, with 1 being “It does not matter to me” and 5 being 
“I feel some are better”. Of the 88 participants the number making choices 1-5 respectively 
was 25 (28%), 9 (10%); 20 (23%), 13 (15%), and 20 (23%), with 1 person not responding. 
These ratings did not differ based on race and sex of respondents; however, marginally more 
participants in the 18-50 age group than the >50 group reported it did not matter (Fisher’s 
exact test P=0.052). More participants in the UW clinic patients group, than the UW NEXT 
Medicine study group also reported it did not matter (Fisher’s exact test P=0.048 
respectively).
DISCUSSION
Incidental findings was the original term used by the scientific community2,17-23 to describe 
findings identified from genomic tests that are not related to the indication for testing. The 
term secondary findings—one of the numerous alternative terms that has been proposed3—
was recently endorsed by the ACMG because it was deemed to describe the intentional 
process of analysis better than other terms.24 ancillary findings has also been used by 
radiology and imaging specialties.5,6,25-27 Yet, UW survey and UNC focus group patients 
participating in our study not only did not prefer any of these terms, but they were strikingly 
consistent in preferring the term “additional findings.” That is, given an option of four terms, 
59% of UW survey respondents ranked the term additional findings above the other terms. 
Only one-third of survey respondents preferred the term “secondary findings.” Similarly, 
UNC focus group participants both volunteered and reached a consensus on “additional” as 
their preferred term. Thus, our findings reveal discordance between the term typically used 
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by the genetics community and by patients’ preferences from both survey data and open-
ended discussion.
This finding may indicate that patients and research participants prefer more familiar words. 
The words “additional” and “secondary”, but not “incidental”, are listed in the Oxford 
3000,28 a list of 3,000 of the “most important words to learn in English” based on the 
criteria of frequency in English across varying types of texts and/or a high degree of 
familiarity to most English users. UNC Focus Group participants also preferred a term that 
was a familiar word.
However, participants also had other reasons for their preferences—they felt the alternative 
words had connotations that were misleading or inaccurate. Explanations that survey 
respondents offered for their choice included the concern that the term “incidental” conveys 
a sense of unimportance. Likewise, focus group participants pointed out that incidental 
results could be diagnostic of a serious health condition, underscoring their perceived 
importance. Consequently, these participants suggested using a broader, neutral term that 
could encompass a range of information. Echoing this sentiment, Dorschner et al,10 
criticized the term secondary findings because it may lead to these findings being interpreted 
as less important than primary findings.
Clearly, patients and providers may understand terms to mean different things, offering 
another potential explanation for why the preferences of patients and geneticists are 
discordant. For instance, one justification for using the term incidental findings is that it 
exists as a medical term with a clear meaning to providers; however, this meaning does not 
appear to be shared by patients. Medically, the term “secondary” is used to mean “due to 
another cause or disease,” as exemplified by the disorder “secondary amenorrhea.” It is 
likely that the participants are not concerned with or aware of the medical usage of the term 
“secondary,” either.
In addition, our findings suggest that greater exposure to the concept of incidental findings 
may affect the extent to which patients perceived it to be important to use terminology they 
deemed to be accurate. Specifically, compared to UW Genetic Medicine Clinic patients, a 
greater proportion of UW NEXT Medicine study participants indicated that they felt some 
terms were better than others. NEXT Medicine participants discussed the concept of 
incidental findings several times as part of the study protocol and consented to be part of a 
trial in which exploring incidental findings was a primary aim; thus, they were likely to have 
spent more time thinking about the concept of incidental findings as it is currently used in 
medical genetics practice.
Several limitations should be noted with respect to these findings. Both the UW survey and 
UNC focus group studies included a relatively small number of participants, the majority of 
which were Caucasian and highly educated, and both studies were conducted at large 
academic medical centers, so these results may not be generalizable to other settings. 
Repeating the surveys and focus groups in a more diverse population would increase the 
generalizability of these results. In addition, the order of alternative terms was not 
randomized in the paper survey given to UW Genetic Medicine clinic patients. However, our 
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findings suggested that the order in which the terms were listed did not affect patient 
preferences. Additional findings was listed third on the paper survey, but was the first choice 
of most. Furthermore, the terms were presented in a random order in the electronic survey 
and there was no difference in first choice response between the two groups.
As genomic sequencing technology becomes more integrated into healthcare, it may 
improve care to ensure the use of standard terminology that is meaningful to patients. The 
gap between the terminology used by providers and what makes the most intuitive sense to 
patients may influence the effectiveness of communication. Using language and terms that 
are familiar and accessible to patients should help ensure that patients are well-informed 
about the various results options available from clinical sequencing laboratories. Facilitating 
patients’ understanding and their ability to make informed choices should also empower 
them to actively consider their options concerning additional findings as they decide whether 
or not to pursue genomic sequencing (e.g., when considering whether to opt out of 
interpreting the ACMG 56 medically actionable genes on exome sequencing tests2).
In summary, despite widespread use of the terms incidental findings and secondary findings 
in medical genetics to describe sequencing results unrelated to the indication for testing, 
patients appear to prefer the more neutral and accessible term: additional findings. Patient 
perceptions and comprehension will be framed by the terms used. As such, medical genetics 
professionals should consider this preference when choosing terms to use as they 
communicate with patients and participants about these findings in the genetics clinic and in 
research studies.
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Figure 1. Rankings of terms sorted by percent of participants in each survey group (paper vs. 
electronic)
The darker hue represents the choices made by participants responding to the paper survey; 
the lighter hue represents choices made by participants responding to the electronic survey
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Table 1
UW survey respondents’ demographic data (N=88)
Genetic Medicine Clinic
(N=31)
NEXT Medicine Study
(N=57)
Total
(N=88)
Sex, n(%)
 Male 13 (41.9%) 28 (49.1%) 41 (46.6%)
 Female 17 (54.8%) 29 (60.9%) 46 (52.3%)
 Not recorded 1 (3.2%) 0 (0%) 1 (1.1%)
Race, n(%)
 White 24 (77.4%) 49 (86.0%) 73 (83.0%)
 Non-white 7 (22.6%) 8 (14.0%) 15 (17.0%)
Age, n(%)
 18- 30 years old 4 (12.9%) 1 (1.8%) 5 (5.7%)
 30-50 years old 17 (54.8%) 21 (36.8%) 38 (43.2%)
 50-70 years old 10 (32.3%) 29 (50.9%) 39 (44.3%)
 Over 70 years old 0 (0%) 6 (10.5%) 6 (6.8%)
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Table 2
UNC NCGENES focus group demographic data (N=37 completed surveys)
Number of participants (N=37)
Sex, n(%)
 Male 10 (27.0%)
 Female 27 (73.0%)
Race/Ethnicity, n(%)
 Non Hispanic
  White 27 (73.0%)
  African-American 3 (8.1%)
  Asian 2 (5.4%)
  Multi/other race 1 (2.7%)
 Hispanic 3 (8.1%)
Education, n(%)
 Bachelor/advanced degree 24 (64.9%)
 Some college/trade school 9 (24.3%)
 High school or less 4 (10.8%)
Marital status, (n%)
 Married 25 (67.6%)
 Never married 5 (13.5%)
 Separated/divorced 7 (18.9%)
Full or part time employment 19 (51.4%)
Health insurance 33 (89.2%)
Number of genetic tests, n(%)
 Never 2 (5.4%)
 One 25 (67.6%)
 More than one 7 (18.9%)
 Not sure/no answer 3 (8.1%)
Understand meaning of prior test?, n(%)
 Yes 25 (67.6%)
 No 4 (10.8%)
 Don’t know/no answer 8 (21.6%)
Haven’t heard of whole exome sequencing,
n(%)
28 (75.7%)
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